Single User
£3750
PDF
66 pages

Osteoarthritis Forecast in 12 Major Markets 2016-2026


Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation of the articular cartilage and sub-chondral bone. OA is actually a collection of diseases rather than one disease per se: can be primary (chronic degenerative disorder related to but not caused by age, with a strong genetic linkage - reports of ~ 60%) or secondary (caused by injury, infection / inflammation and as a consequence of other chronic diseases).

This report provides the current prevalent population for Osteoarthritis across 12 Major Markets (USA, France, Germany, Italy, Spain, UK, Russian Federation, Canada, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Osteoarthritis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

There are a number of conditions that co-occur with OA including:

  • Congenital joint abnormalities (Marfan syndrome)
  • Metabolic defects (eg, hemochromatosis, Wilson disease)
  • Infections (causing post infectious arthritis)
  • Endocrine and neuropathic diseases
  • Rheumatoid Arthritis
  • Gout
  • Chondrocalcinosis
  • Obesity

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Osteoarthritis market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Osteoarthritis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Osteoarthritis’s prevalent population.
  • Identify sub-populations within Osteoarthritis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Osteoarthritis patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
    • Additional data available on request
  • Top-line prevalence for Osteoarthritis
  • Symptomatic OA patients
    • Prevalence of Symptomatic OA
    • BMI Status of Symptomatic OA
    • BMD Category in Symptomatic OA
    • Comorbidities of Symptomatic OA patients
  • Hip Osteoarthritis
    • Severity of Hip OA
    • Comorbidities and features of patients with Hip OA
    • Pain and Hip OA
  • Knee Osteoarthritis
    • Severity of Knee OA
    • Comorbidities and features of patients with Knee OA
  • Joint Replacement in OA
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • Kellgren-Lawrence grading for osteoarthritis
  • Prevalence of OA, total (000s)
  • Prevalence of OA, males (000s)
  • Prevalence of OA, females (000s)
  • Prevalence of Symptomatic OA, total (000s)
  • Symptomatic OA patients by BMI status, total (000s)
  • Symptomatic OA patients by BMD category, total (000s)
  • Symptomatic OA patients with elevated CRP, total (000s)
  • Symptomatic OA patients with hypertension, total (000s)
  • Symptomatic OA patients with diabetes, total (000s)
  • Symptomatic OA patients with Hip OA, total (000s)
  • Symptomatic OA patients with Hip OA, males (000s)
  • Symptomatic OA patients with Hip OA females (000s)
  • Hip OA patients by severity, total (000s)
  • Hip OA patients with history of OA in hands, total (000s)
  • Hip OA patients with history of OA in knees, total (000s)
  • Hip OA patients with Heberden’s nodes, total (000s)
  • Hip OA patients with Osteophytes, total (000s)
  • Hip OA patients with Sclerosis, total (000s)
  • Hip OA patients with Cysts, total (000s)
  • Hip OA patients with bony enlargement of knee, total (000s)
  • Hip OA patients with femoral head remodelling, total (000s)
  • Hip OA patients with femoral buttressing, total (000s)
  • Hip OA patients with lateral thigh pain, total (000s)
  • Hip OA patients with pain in the groin area, total (000s)
  • Hip OA patients with pain radiating to the knee, total (000s)
  • Hip OA patients with pain on prolonged ambulation, total (000s)
  • Symptomatic OA patients with Knee OA, total (000s)
  • Symptomatic OA patients with Knee OA, males (000s)
  • Symptomatic OA patients with Knee OA, females (000s)
  • Knee OA patients by severity, total (000s)
  • Knee OA patients with history of significant trauma, total (000s)
  • Knee OA patients with history of swelling, total (000s)
  • Knee OA patients with bony enlargement of knee, total (000s)
  • Knee OA patients with change in knee structure/function, total (000s)
  • Knee joint replacement in OA patients, total (000s)
  • Hip joint replacement in OA patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • USA prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • France prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • France prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Germany prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Germany prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Italy prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Italy prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Spain prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Spain prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • UK prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • UK prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Russian Federation prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Russian Federation prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Canada prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Canada prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Brazil prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Brazil prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • Japan prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • Japan prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • India prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • India prevalence of osteoarthritis by 5-yr age cohort, females (000s)
  • China prevalence of osteoarthritis by 5-yr age cohort, males (000s)
  • China prevalence of osteoarthritis by 5-yr age cohort, females (000s)
List of Figures
  • Joint damage caused by osteoarthritis in the knee joint
  • Visual representation of stages of osteoarthritis in the knee joint
Brazil, Canada, China, France, Germany, India, Italy, Japan, Russian Federation, Spain, United Kingdom, United States of America